₹4,800, which is more than 80% less than the price at which the branded version of this product will be available to governments in the developed world,' says Mylan NEW DELHI: Mylan on Monday announced that it had received an emergency use authorisation from the Drug Controller General of India for its licensed generic of remdesivir for treatment of covid-19 and that the company has priced the drug at ₹4,800 per vial.“The drug will be launched under the brand name DESREMTM in India and will be available to patients in July at a price of ₹4,800, which is more than 80% less than the price at which the branded version of this product will be available to governments in the developed world," Mylan said in a statement.Gilead Sciences Inc had.